A dangerous bias
Sir, In their recently published paper (Domar et al., 2013) , the authors' conclusion that 'there is little evidence of benefit from the antidepressants prescribed for the majority of women of childbearing age-and there is ample evidence of risk', is based on a biased reading of the literature. Rather than including a balanced analysis of the studies on the subject, they cite five articles supporting their conclusions, out of thousands. For instance, a recent meta-analysis examining six placebo-controlled studies found a significant treatment effect for patients with non-severe depression (Stewart et al., 2012) . Another recent re-analysis of the Fournier article they cite concluded that Fournier's results were based on unreliable data (Isacsson and Adler, 2012) . Moreover, a number of the articles cited in the paper support the conclusion that antidepressants are an effective treatment for depression (e.g. DeRubeis et al., 1999; Faramarzi et al., 2008a,b) .
Nor is this all. The authors suggest that a lack of data on antidepressants in pregnant women amounts to proof of their inefficacy. This is wrong on two counts. First, even if there were no data, it would be far more reasonable to assume that, until proven otherwise, drugs shown to work in the general population would also work in specific populations. Secondly, if there is a relative dearth of data, it is only because conducting randomized control trials of medication use in pregnancy is unethical. However, data does exist, in the form of two studies looking at rates of relapse in women who continue or discontinue their antidepressants during pregnancy (Cohen et al., 2006; Yonkers et al., 2011) . While Cohen et al. found a significant increase in relapse amongst women who discontinued their medication during pregnancy, Yonkers did not find a difference amongst the two groups. In glossing over the subtleties that could account for these different results, Domar et al. miss Yonker's conclusion that these two studies together likely suggest that relapse is higher for some women, but not all.
Amazingly, Domar et al. also claim that 'there is overwhelming evidence that cognitive behavioral therapy is equivalent to antidepressant medication', citing the Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines (Parikh et al., 2009) . In fact, CANMAT concludes that 'combined [my emphasis] antidepressant and CBT or IPT are recommended as first-line treatments for acute MDD', because evidence suggests that combined treatment is superior to either medication or therapy alone.
Possibly, Domar's error originates with the assumption that the majority of women treated with antidepressants during pregnancy have mild depression that would respond to psychotherapy. And yet, there exists no evidence to support this assumption. Nor does this assumption takes into account the fact that many pregnant women with depression have comorbid psychiatric disorders, which often require medication management. Perhaps from Domar's perspective, as someone who studies 'distress' in infertile women, it may not be clear that Major Depressive Disorder is a distinct clinical entity.
Treating depression in pregnant women is complicated; as enumerated in the APA and ACOG guidelines, a number of factors should be considered in determining the best treatment for a depressed pregnant woman (Yonkers et al., 2009) . Along with the severity of the depression being treated, for instance, clinicians must also take into account a women's history of response to antidepressants and other treatments. For patients with clear history of decompensating off medication, and improving upon re-initiation, or for women who have already failed to improve despite psychotherapy treatment, antidepressants play an important role in treatment.
The authors minimize the risks of depression during pregnancy, and conclude that, 'In short, it is unclear from the available evidence whether there is an association between pregnancy complications and depression'. Depressed pregnant women are more likely to receive inadequate prenatal care (Kelly et al., 1999) , to use tobacco, alcohol and illicit substances during pregnancy (Horrigan et al., 2000) , to not gain sufficient maternal weight (Bennett et al., 2004) , and in severe cases, depression can lead to suicide. Untreated depression during pregnancy has also been associated with an elevated risk of pre-eclampsia (Kurki et al., 2000; Shamsi et al., 2010) , a significant cause of morbidity and mortality. The most recent meta-analysis on outcomes associated with prenatal depression identified an increased risk of preterm delivery and low birthweight (Grote et al., 2010) . Not only are women less able to care for themselves, but they are less able to emotionally prepare for the birth in their personal relationships, at work, and at home. As Domar's own studies suggest, depression can decrease fertility, and successful treatment can improve fertility rates (Domar et al., 1999) . Recent studies suggest there may be long-term developmental effects of depression in pregnancy on children, even controlling for post-partum depression (Deave et al., 2008; O'Connor et al., 2002) . Finally, depression during pregnancy increases the risk of post-partum depression, which has been well documented to be associated with negative developmental outcomes.
While the number of women taking antidepressants during pregnancy is rising, there is still ample evidence that depression during pregnancy is under-recognized and under-treated. Such a one-sided paper, only adds harmful hype to an already stigmatized issue, at a time when balance is most needed.
